- Home
- WULF vs RCKT Comparison
WULF vs RCKT Comparison
Compare WULF & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WULF | RCKT |
|---|---|---|
| Founded | 1952 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 394.2M |
| IPO Year | 1999 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WULF | RCKT |
|---|---|---|
| Price | $16.25 | $2.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | $20.86 | ★ $29.73 |
| AVG Volume (30 Days) | ★ 24.3M | 1.5M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | ★ $168,455,000.00 | N/A |
| Revenue This Year | $126.80 | N/A |
| Revenue Next Year | $162.52 | $64.28 |
| P/E Ratio | ★ N/A | $4.58 |
| Revenue Growth | ★ 20.28 | N/A |
| 52 Week Low | $10.47 | $2.53 |
| 52 Week High | $29.84 | $5.45 |
Technical Indicators
Market Signals| Indicator | WULF | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 34.62 |
| Support Level | $14.51 | N/A |
| Resistance Level | $18.01 | $3.67 |
| Average True Range (ATR) | 0.88 | 0.20 |
| MACD | 0.16 | -0.07 |
| Stochastic Oscillator | 45.13 | 5.12 |
Price Performance
Historical ComparisonAbout WULF TeraWulf Inc.
TeraWulf Inc develops and operates large-scale digital infrastructure designed for AI and high-performance computing workloads. The Company owns and operates energy infrastructure across key U.S. power markets, providing large-scale, contiguous power capacity for next-generation compute. Its strategic sites offer direct grid connectivity and, in select locations, integrated generation, creating a foundation for scalable compute infrastructure. Built on deep expertise in energy markets and grid integration, TeraWulf approaches compute infrastructure from the foundation up- securing power, developing scalable sites, and operating with disciplined execution.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.